NCT03737955View on ClinicalTrials.gov

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Gemtuzumab Ozogamicin

Receive IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

98109

RECRUITING

Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Washington

OTHER